A Study Evaluating Safety and Efficacy of the Addition of ABT-888 Plus Carboplatin Versus the Addition of Carboplatin to Standard Chemotherapy Versus Standard Chemotherapy in Subjects With Early Stage Triple Negative Breast Cancer

Clinical trial NCT02032277 · COMPLETED

Trial details

NCT number: NCT02032277
Sponsor: AbbVie
Status: COMPLETED
Phase: Phase 3
Study type: INTERVENTIONAL

Triple Negative Breast Cancer

Start date: 2014-04-02
Primary completion: 2016-03-18
Enrollment: 634

View on ClinicalTrials.gov

Track trials programmatically

Sponsors, conditions and status changes through the Atlas API.